Overview of Nomenclature of Nuclear Receptors

@article{Germain2006OverviewON,
  title={Overview of Nomenclature of Nuclear Receptors},
  author={Pierre Germain and Bart Staels and Catherine Dacquet and Michael Spedding and Vincent Laudet},
  journal={Pharmacological Reviews},
  year={2006},
  volume={58},
  pages={685 - 704}
}
Nuclear receptor pharmacology has, to a certain extent, led the way, compared with other receptor systems, in the appreciation that ligands may exert very diverse pharmacology, based on their individual chemical structure and the allosteric changes induced in the receptor/accessory protein complex. This can lead to very selective pharmacological effects, which may not necessarily be predicted from the experience with other agonists/partial agonists/antagonists. If this is the case, then drug… 

Figures and Tables from this paper

Development of Nuclear Receptor Modulators.

Characteristics of nuclear receptors as target family, strategies of hit and lead identification, and the variety of methods for in vitro characterization of nuclear receptor modulators are summarized.

Nuclear Receptors and Their Selective Pharmacologic Modulators

The development and pharmacology of a range of selective nuclear receptor modulators are reviewed, where ligands display agonist/partial agonist-binding domain of nuclear receptors function in a tissue or gene selective manner.

A structural perspective on nuclear receptors as targets of environmental compounds

A structural and mechanistic view of endocrine disrupting action using estrogen receptors α and β, (ERα/β), peroxisome proliferator activated receptor γ (PPARγ), and their respective environmental ligands as representative examples are provided.

Evolution of Nuclear Receptors and Ligand Signaling: Toward a Soft Key-Lock Model?

Nuclear Receptors, Chemistry of

The dogma that all nuclear receptors, especially the large subset of constitutively active receptors, will have ligands and will represent tractable drug targets is challenged, and the “pharmacologic future” for such orphan nuclear receptors may reside outside of the ligand-binding pocket.

IDPs and their complexes in GPCR and nuclear receptor signaling.

Alternative retinoid X receptor (RXR) ligands

Therapeutic potential of nuclear receptors

This review provides an overview on the molecular classification and disease relevance of NRs, as well as on recent advances in pharmacologic (pre-clinical targeting approaches and patent applications, using various databases and websites.

The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors

The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug
...

References

SHOWING 1-10 OF 238 REFERENCES

Principles for modulation of the nuclear receptor superfamily

This review provides a general overview of the mechanism of action of nuclear receptors and explores the various factors that are instrumental in modulating their pharmacology.

The RXR heterodimers and orphan receptors

Coregulator function: a key to understanding tissue specificity of selective receptor modulators.

Increased understanding of the effect of cellular environment on nuclear receptors and their coregulators has the potential to open the field of SRM discovery and research to many members of the nuclear receptor superfamily.

Activation of nuclear receptors: a perspective from structural genomics.

Molecular basis of agonism and antagonism in the oestrogen receptor

The crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17β-oestradiol, and the selective antagonist raloxifene provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties.

A two-site model for antiestrogen action

...